Table 3 The mean spirometric values and the mean serum concentrations of examined cytokines in patients with progressive and non-active sarcoidosis and in radiological stage I,II and III
|  | Progressive, active sarcoidosis n = 18 | Non active sarcoidosis n = 25 | Sarcoidosis Stage I n = 10 | Sarcoidosis Stage II n = 20 | Sarcoidosis Stage III n = 13 |
|---|---|---|---|---|---|
|  | (mean ± SEM) | (mean ± SEM) | (mean ± SEM) | (mean ± SEM) | (mean ± SEM) |
| Â | Median (Interquartile range) | Median (Interquartile range) | Median (Interquartile range) | Median (Interquartile range) | Median (Interquartile range) |
Age (years) | 35.1 ± 1.9 | 36.2 ± 1.7 | 30.3 ± 1.5 | 35.7 ± 1.9 | 40.3 ± 2.3 |
32.5 (30.0–40.0) | 34.0 (29.0–40.0) | 29.0 (29.0–30.8) | 33.5 (30.5–39.0) | 40.0 (33.5–44.3) | |
FEV1 (% of predicted) | 87.1 ± 2.0 | 85.4 ± 2.4 | 87.7 ± 2.7 | 87.2 ± 1.8 | 83.1 ± 4.3 |
84.0 (81.0–92.0) | 87.0 (80.0–94.0 | 90.0 (82.8–101.0) | 85.0 (80.5–97.3) | 85.0 (81.0–91.5) | |
FVC (% of predicted) | 96.8 ± 3.4 | 95.9 ± 2.7 | 100.2 ± 3.7 | 97.6 ± 2.8 | 90.7 ± 4.6 |
95.0 (88.0–108.0) | 98.0 (91.0–103.0) | 100.0 (96.0–105.5) | 100.0 (89.5–104.0) | 90.0 (82.8–101.0) | |
FEV1%VC (%) | 75.6 ± 1.8 | 75.7 ± 1.2 | 77.0 ± 1.8 | 74.8 ± 1.5 | 75.8 ± 2.2 |
74.5 (70.0–82.0) | 75.5 (71.0–79.0) | 77.0 (74.0–80.0) | 74.0 (70.5–77.5) | 75.0 (68.8–83.5) | |
Angiopoeitin-2 (pg/ml) | 239.1 ± 37.9 | 208.4 ± 41.5 | 355.6 ± 66.0* | 206.0 ± 37.9 | 142.2 ± 42.2 |
220.0 (120.1–380.6) | 169.0 (69.9–281.5) | 361.7 (170.0–518.8) | 178.3 (98.6–310.0) | 89.0 (13.5–192.9) | |
Folistatin (pg/ml) | 372.9 ± 51.9 | 346,456 ± 41.1 | 448.5 ± 59.1 | 328.8 ± 46.4 | 331.9 ± 62.2 |
348.8 (258.6–466.7) | 304.6 (206.1–444.0) | 406.5 (265.1–636.5) | 296.6 (211.7–416.8) | 357.9 (154.5–472.3) | |
GM-CSF (pg/ml) | 28.8 ± 8.0 | 33.7 ± 5.7 | 45.4 ± 12.9 | 32.4 ± 6.0 | 20.1 ± 6.9 |
12.8 (10.3–32.0) | 32.1 (7.6–56.0) | 33.4 (10.5–88.2) | 24.2 (8.3–52.1) | 12.7 (2.5–34.6) | |
IL-8 (pg/ml) | 28.4 ± 7.7 | 32.4 ± 4.4 | 47.7 ± 11.8 | 29.0 ± 4.6 | 20.4 ± 4.7 |
14.5 (13.7–22.7) | 39.2 (11.9–48.7) | 42.8 (15.1–85.7) | 18.4 (13.3–46.6) | 12.8 (10.7–28.8) | |
PDGF-BB (pg/ml) | 5304.0 ± 786.5 | 5689.8 ± 772.3 | 5865.1 ± 856.4 | 5564.5 ± 863.6 | 5213.5 ± 1123.2 |
4591.3 (3054.5–6419.3) | 5547.9 (2724.6–7594.7) | 5044.5 (3544.5–8742.6) | 4757.8 (2655.4–7972.2) | 4575.5 (1536.6–8612.5) | |
PECAM-1 (pg/ml) | 2537.3 ± 330.4 | 2456.6 ± 327.9 | 3126.1 ± 328.6 | 2377.3 ± 394.0 | 2175.5 ± 389.7 |
2469.8 (1502.1–3418.4) | 2190.3 (1295.8–2854.1) | 2596.1 (2323.9–4164.1) | 1926.5 (1262.9–2818.9) | 2290.7 (862.3–3340.9) | |
VEGF (pg/ml) | 93.9 ± 13.7 | 84.9 ± 8.6 | 116.8 ± 21.5 | 87.9 ± 9.4 | 68.29 ± 9.6 |
79.9 (60.6–117.8) | 87.6 (53.5–101.2) | 98.8 (61.5–165.9) | 87.9 (60.4–100.3) | 62.7 (34.3–100.4) |